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Abstract
Endogenous pregnane neurosteroids are allosteric modulators at γ-aminobutyric acid type-A
(GABAA) receptors at nanomolar concentrations. There is direct evidence for multiple distinct
neurosteroid binding sites on GABAA receptors, dependent upon subunit composition and
stoichiometry. This view is supported by the biphasic kinetics of various neuroactive steroids,
enantioselectivity of some neurosteroids, selective mutation studies of recombinantly expressed
receptors and the selectivity of the neurosteroid antagonist (3α,5α)-17-phenylandrost-16-en-3-ol
(17PA) on 5α-pregnane steroid effects on recombinant GABAA receptors expressed in Xenopus
oocytes and native receptors in dissociated neurons. However, it is unclear whether this antagonist
action is present in a mature mammalian system. The present study evaluated the antagonist activity
of 17PA on neurosteroid agonists both in vivo and in vitro by examining the effects of 17PA on 5α-
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pregnane-induced sedation in rats, native mature GABAA receptor ion channels utilizing the chloride
flux assay and further studies in recombinant α1β2γ2 receptors. The data show that 17PA
preferentially inhibits 3α,5α-THP vs. alphaxalone in vivo, preferentially inhibits 3α,5α-THDOC vs.
alphaxalone potentiation of GABA-mediated Cl- uptake in adult cerebral cortical
synaptoneurosomes, but shows no specificity for 3α,5α-THDOC vs. alphaxalone in recombinant
α1β2γ2 receptors. These data provide further evidence of the specificity of 17PA and the
heterogeneity of neurosteroid recognition sites on GABAA receptors in the CNS.
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1. Introduction
GABAA receptor Cl- channels are the principal mediators of rapid synaptic inhibition in the
central nervous system (Sieghart and Sperk, 2002). Pregnane steroids have been shown to be
potent modulators of GABAA receptors (for reviews see (Belelli and Lambert, 2005; Paul and
Purdy, 1992). Patch-clamp electrophysiological studies have shown that the progesterone
metabolite 3α-hydroxy-5α-pregnan-20-one (3α,5α-THP) and the deoxycorticosterone
metabolite 3α,21-dihydroxy-5α-pregnan-20-one (3α,5α-THDOC) act as equipotent allosteric
modulators of GABAA receptors at exceptionally low concentrations by promoting the open
state of the ion channel, whilst exerting no direct effect on single channel conductance
(Callachan et al., 1987; Lambert et al., 1995; Majewska et al., 1986). These neurosteroids have
also been shown to act as equally efficacious allosteric modulators of mature native GABAA
receptors by enhancing GABAA receptor agonist-induced 36Cl- uptake into cerebral cortical
synaptoneurosomes with nanomolar potency (Belelli and Gee, 1989; Morrow et al., 1987).
There is evidence that distinct neurosteroid binding sites exist on GABAA receptors. Multiple
distinct neurosteroid recognition sites on GABAA receptors have recently been identified
(Hosie et al., 2006). Most GABAergic neuroactive steroids potentiate GABA actions on Cl-
uptake (Morrow et al., 1990) or Cl- conductance (Puia et al., 1990) with biphasic activation
curves. Additionally, the enantioselectivity of the GABAA modulatory and anesthetic
properties of 3α,5α-THP, with the synthetic ent-3α,5α-THP being less potent (Wittmer et al.,
1996) supports the identification of multiple steroid recognition sites.
The development of the neurosteroid antagonist (3α,5α)-17-phenylandrost-16-en-3-ol (17PA)
has provided further evidence for the existence of multiple neurosteroid binding sites on
GABAA receptors (Mennerick et al., 2004). 17PA has been shown to selectively antagonize
the modulatory effects of 3α,5α-THP, but not 3α,5β-THP, at recombinant GABAA receptors
expressed in Xenopus oocytes and native GABAA receptors in dissociated hippocampal
neurons (Mennerick et al., 2004). These data support the notion that distinct neurosteroid
binding sites may exist independently on GABAA receptors for 5α- and 5β-pregnane steroids
(Mennerick et al., 2004).
While the previous electrophysiological studies of recombinant GABAA receptors have
convincingly shown the direct antagonism of the GABA-modulatory effects of 5α-pregnane
steroids by 17PA, the receptors studied were expressed in host cells that may possess different
phosphorylation and signaling mechanisms from their neuronal counterparts. Additionally, the
dissociated neurons were obtained from rats on post-natal day 1-3 and may not be expected to
have mature receptors reflecting the subunit composition and stoichiometry of adult neurons
(Bovolin et al., 1992). Although studies of tadpole loss of righting reflex have further supported
the neurosteroid antagonist profile of 17PA in vivo, it is unknown whether similar effects would
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be found in mammalian systems, particularly due to differences in receptor subtype
distribution, subunit expression and amino acid sequence divergence between amphibians and
mammals. Therefore, it was the purpose of the present study to compare the neurosteroid
antagonist activity of 17PA in vivo in a mammalian system with recombinant α1β2γ2 receptors
studied in vitro. We investigated the direct administration of 17PA into the rat brain and
examined its effects on neurosteroid-induced sedation, as well as examining its
pharmacological action on native mature cerebral cortical GABAA receptors utilizing the
chloride flux technique and recombinant α1β2γ2 receptors using patch clamp
electrophysiology. We chose to study α1β2γ2 receptors since these are the most abundant
receptor subtype in mammalian brain and represents greater than 50% of GABAA receptors in
cerebral cortex (Kralic et al., 2002).
2. Methods
2.1 Animals
Adult male Sprague-Dawley rats (N = 152, Harlan, Indianapolis, IN, USA) purchased at
approximately 250 g at the start of experiments were used as test subjects. The rats were housed
individually in plastic cages and were provided access to food (Teklad, Harlan, Indianapolis,
IN, USA) and water ad libitum. The illumination in the vivarium was maintained on a 12-hour
light/dark cycle (lights on at 0700 hours) with temperature maintained at 23 °C. All procedures
were approved by the Institutional Animal Care and Use Committee and conducted according
to the “Guide to the Care and Use of Laboratory Animals” (National Research Council, 1996).
2.2 Drug Preparation
17PA was synthesized as previously described (Mennerick et al., 2004). 17PA was dissolved
in a vehicle composed of 35% β-cyclodextrin (w/v) (Sigma-Aldrich, St Louis, MO, USA) and
sterile artificial cerebrospinal fluid (125 mM NaCl, 2.5 mM KCl, 5 mM Na2HPO4, 1 mM
MgCl2·6H2O, 1.2 CaCl2·2H2O, 5 mM D-glucose, pH to 7.4 with NaOH). 3α,5α-THP and 3α,
5α-THDOC were purchased from Dr. Robert Purdy, Scripps Institute, La Jolla, California,
USA. 3α,5α-THP was dissolved in a vehicle composed of 20% β-cyclodextrin (w/v) and 0.9%
NaCl. Alphaxalone and pregnenolone sulfate were purchased from Steraloids (Newport, RI,
USA) and dissolved in a vehicle composed of 20% β-cyclodextrin (w/v) and 0.9% NaCl. For
chloride flux experiments 17PA, alphaxalone, pregnenolone sulfate, 3α,5α-THP and 3α,5α-
THDOC were dissolved in 100% dimethyl sulfoxide and diluted in assay buffer to a final
dimethyl sulfoxide concentration of ≤ 0.4%.
2.3 Cannulae Implantation
Rats were anesthetized with ketamine (50 mg/kg) and xylazine (10 mg/kg) prepared for aseptic
surgery and secured into a stereotaxic instrument (David Kopf, Instruments, Tujunga, CA,
USA). Stainless steel guide cannulae (22 gauge, Plastics One, Roanoke, VA, USA) aimed at
1 mm dorsal of either the right or the left lateral ventricles were implanted using the following
stereotaxic coordinates: -0.92 mm from bregma; ± 1.4 mm lateral from the midline; 2.4 ventral
to the cortical surface (Hodge, 1994). The guide cannulae were held in place by dental resin
anchored to four stainless steel screws (Plastics One, Roanoke, VA, USA) fixed to the skull.
All measurements were taken from flat skull. Rats were provided with buprenorphine (0.05
mg/kg, ip) post-operatively for pain relief and allowed to recover for at least 7 days prior to
the initiation of experiments.
2.4 I.C.V. Drug Administration
All rats were handled extensively prior to the initiation of i.c.v. procedures in order to reduce
stress and become habituated to manipulation of the guide cannulae. Rats were placed in plastic
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containers to reduce movement and i.c.v. injections were performed on conscious unrestrained
animals. A 28-guage injector was connected to a 10 μl glass Hamilton syringe via PE-50
catheter tubing filled with sterile de-ionized water. An air-bubble (1 μl) was drawn to the distal
end of the catheter tubing to separate the 17PA or vehicle solution and the sterile de-ionized
water. To ensure proper drug delivery, precise flow of the i.c.v. solution was verified by noting
the movement of the air-bubble down the catheter tubing by visual inspection during each i.c.v.
infusion. Obturators were removed and the sterile 28-gauge injector was inserted to a depth 1
mm beyond the end of the guide cannulae into either the left or right lateral ventricle. During
each i.c.v. infusion, 17PA or vehicle was infused in a total volume of 10 μl over a 4 min period.
The injector remained in place for an additional 4 min to allow for drug diffusion. New sterile
obturators were inserted after removal of the injectors. Following drug diffusion, the rats were
then fitted into an adjustable plastic restrainer exposing the tail and the neuroactive steroid
(i.e., 3α,5α-THP or alphaxalone) was administered intravenously into the lateral tail vein. To
verify correct placement of the needle and proper i.v. drug administration, a small quantity of
blood was noted to ‘flash’ back into the hub of the needle. In order to minimize the number of
animals needed for the in vivo sedative/hypnosis studies, all rats received consistently either
17PA or vehicle i.c.v. across multiple doses of steroid (i.e., 3α,5α-THP or alphaxalone). 10
nmoles of 17PA (10 μl of 1 mM 17PA) was the highest dose of 17PA attainable for the in
vivo cannulation experiments. Preliminary experiments indicated that higher concentrations of
17PA were insoluable.
At the end of all experiments, the rats were sacrificed by CO2 inhalation followed by
decapitation. Correct placement of the guide cannula was verified by infusion of 10 μl of the
dye, methyl green (1%) dissolved in the i.c.v. vehicle over 4 min. There was an additional 4
min to allow for diffusion of the dye-i.c.v. vehicle followed by removal of the brain and gross
sectioning through the cannula tract. Visualization of the methyl green dye on the wall of the
lateral ventricle indicated correct placement of the guide cannula.
2.5 Assessment of Sedation/Hypnosis
Sedation/hypnosis was measured by loss of righting reflex. Loss of righting reflex was defined
as the inability of the rats to right themselves three times when placed in a supine position
during a one-min interval.
2.6 Chloride Uptake Analysis
The pharmacological actions of 17PA on native GABAA receptors were studied in a subcellular
vesicle preparation (synaptoneurosomes) as previously described (Kumar et al., 2005; Morrow
et al., 1990). Brains were rapidly removed following decapitation and placed into ice-cold
assay buffer (20 mM Hepes, 118 mM NaCl, 4.7 mM KCl, 1.2 MgSO4, 2.5 mM, CaCl2 pH 7.4
with Tris-Base). Cerebral cortices were isolated and homogenized manually in ice-cold assay
buffer using a glass-glass homogenizer (5 strokes). The homogenate was brought to volume
(30 ml) and filtered through three layers of 160 μm nylon mesh followed by additional filtration
through a 10 μm filter (Millipore, Billerica, MA, USA). The homogenate was then centrifuged
at 1000 × g for 15 min followed by resuspension in 30 ml of ice-cold assay buffer and
subsequent homogenization in a Teflon-glass homogenizer (3 strokes). The homogenate was
further centrifuged twice more at 1000 × g before final resuspension of the synaptoneurosomal
pellet in assay buffer to yield a final protein concentration of approximately 6 mg/ml. Aliquots
(200 μL) of homogenate were dispensed to each assay tube and pre-incubated at 30 °C for 12
min. Muscimol-stimulated 36Cl- uptake was initiated by the addition of 0.4 μCi 36Cl
(Amersham Biosciences, Amersham, England, UK) in the presence of an EC20 concentration
(1.5 μM) of muscimol alone or in conjunction with 3α,5α-THDOC, alphaxalone and 17PA.
The solution was vortexed and uptake was terminated after 5 seconds by addition of 4 ml of
ice-cold assay buffer containing 100 μM picrotoxin (Sigma-Aldrich, St Louis, MO, USA)
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under rapid vacuum filtration over G6 filters (Fisher Scientific, UK) using a single manifold
filter apparatus (Hoeffer, San Francisco, CA, USA). Following two more picrotoxin washes,
filters were allowed to dry and radioactive counts were determined by liquid scintillation
spectroscopy.
2.7 Data analysis
All results are expressed as mean ± S.E.M. The duration of the loss of righting reflex response
was measured. loss of righting reflex durations (total sleep time) for both 3α,5α-THP and
alphaxalone were analyzed by a two-way repeated measures analysis of variance (ANOVA)
with one between-subjects factor, i.c.v. 17PA dose, and one within-subjects factor, i.v. 3α,
5α-THP or alphaxalone dose. Multiple comparison post-hoc tests were performed using
Tukey’s t. In addition to total sleep time, dose-effect data for animals receiving i.c.v. 17PA or
vehicle were fitted to the quantal analysis equation of the form
(1)
were p is percent of the population anesthetized, D is the drug dose, n is the slope factor and
ED50 is the drug dose for half-maximal effect (Waud, 1972). Unpaired t-tests were performed
using the i.c.v. 17PA and vehicle mean ED50 and s.e.m. estimated from the quantal analysis
equation for both 3α,5α-THP and alphaxalone. Statistical significance was defined as p < 0.05.
For chloride flux experiments, data are expressed as net 36Cl- uptake or potentiation in nmole/
mg of protein. The net uptake represents total chloride uptake in the absence of muscimol
(basal). Potentiation represents the increase in 36Cl- over and above, but not including, that
produced by muscimol stimulation. Concentration-response curves were fitted to the equation
of the form
(2)
where E is potentiation of muscimol-stimulated 36Cl- uptake, Emax is the maximal potentiation
and A is the concentration of steroid. Protein determinations were made using the bicinchoninic
acid (BCA) protein assay kit (Pierce, Rockford, IL, USA).
2.8 Electrophysiology
Stage V-VI oocytes were harvested from mature female Xenopus laevis (Xenopus One,
Northland, MI) and were defolliculated and injected with rat α1, β2 and γ2L subunit cRNA
transcribed using the mMESSAGE mMachine kit (Ambion, Austin, TX, USA). Oocytes were
incubated up to 5 days at 18° C in ND96 medium containing (in mM): 96 NaCl, 1 KCl, 1
MgCl2, 2 CaCl2 and 5 HEPES at pH 7.4, supplemented with pyruvate (5 mM), penicillin (100
U/ml), streptomycin (100 μg/ml) and gentamycin (50 μg/ml). Cells were clamped at −70 mV
using an OC725 two-electrode voltage-clamp amplifier (Warner Instruments, Hamden, CT,
USA), and current at the end of 30 s drug applications was measured for quantification of
current amplitudes. Steroids and 17PA were co-applied with GABA by gravity perfusion.
Acquisition and analysis were performed with pCLAMP 9.0 (Molecular Devices, Union City,
CA, USA). Statistical differences were determined using a two-tailed Student’s t-test.
3. Results
3.1 Loss of Righting Reflex
We examined whether i.c.v. administration of the putative neurosteroid antagonist 17PA could
attenuate the sedative/hypnotic action of 3α,5α-THP and the synthetic neurosteroid
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alphaxalone. Loss of righting reflex was used as the primary measure of sedation/hypnosis.
Pre-treatment with i.c.v. administration of 17PA resulted in a rightward shift in the loss of
righting reflex dose-response curve, decreasing the percentage of animals (n = 15 per 17PA
dose) exhibiting loss of righting reflex in response to 3α,5α-THP (0.625 – 5.0 mg/kg, i.v.).
3α,5α-THP in the presence of i.c.v. vehicle had an effective dose (ED50) of 1.91 ± 0.02 mg/kg
with a slope factor of 4.8 ± 0.28, whilst 3α,5α-THP in the presence of 17PA (10 nmoles) showed
a significantly higher ED50 of 2.4 ± 0.01 (t = -19.85, df = 28, P < 0.05) with a slope factor of
8.1 ± 0.12 (Fig 1). 17PA pre-treatment reduced the total sleep time induced by 3α,5α-THP
(Two-way ANOVA, F = 6.9, df =1,135, P < 0.05). Additional post-hoc analyses showed that
17PA pre-treatment significantly attenuated total sleep time induced by 3α,5α-THP at 2.0 and
2.5 mg/kg (Tukey’s t, P <0.05).
In contrast, i.c.v. administration of 17PA did not significantly alter sedative/hypnotic action
of the synthetic neurosteroid, alphaxalone. Pre-treatment with 17PA (10 nmoles, n = 11)
produced no significant shift in the percentage of animals exhibiting loss of righting reflex to
intravenous administration of alphaxalone (1.25 – 10.0 mg/kg). Alphaxalone in the presence
of i.c.v. vehicle (n = 11) produced an ED50 of 2.3 ± 0.13 (Mean ± S.E.M.), whilst pre-treatment
with 17PA produced no significant change in the sedative potency of alphaxalone with an
ED50 of 2.26 ± 0.30 (t = -0.2, df= 20, P = 0.844) (Fig 2). Additionally, i.c.v. administration of
17PA did not significantly reduce total sleep time under alphaxalone as revealed by a two-way
repeated measures ANOVA (F = 0.58, df =1,104, P = 0.46).
3.2 Chloride Flux and Electrophysiology
17PA (0.1 μM – 100 μM) did not significantly alter basal 36Cl- uptake in synaptoneurosomes
(One-way ANOVA, F = 0.2, df = 10, p = 0.89). Additionally 17PA did not significantly
alter 36Cl- uptake stimulated by muscimol (1.5 μM) (F = 0.62, df = 11, p = 0.62) demonstrating
no direct antagonist action at native GABAA receptors (Fig 3).
The antagonist action of 17PA on neurosteroid potentiation of muscimol induced Cl- flux was
assessed across a range of doses (1nM - 30μM) for both the physiological neurosteroids, 3α,
5α-THP and 3α,5α-THDOC. 17PA did not produce a significant rightward shift in the dose-
response curve for 3α,5α-THP (Fig 4a). However, 17PA significantly reduced the Emax of 3α,
5α-THP potentiation, (11.78 versus 19.41 nmoles/mg prot., t = 2.351, df = 16, p < 0.05). In an
similar manner, 17PA did not produce a significant rightward shift in the dose-response curve
for 3α,5α-THDOC (Fig 4b). However, 17PA significantly reduced the Emax of 3α,5α-THDOC
potentiation, (11.81 versus 20.82 nmoles/mg prot., t = 3.24, df = 16, p < 0.01) therefore
attenuating maximal 3α,5α-THDOC potentiation of muscimol-stimulated 36Cl- uptake.
Furthermore, 17PA altered the characteristics of the 3α,5α-THDOC dose-response curve, such
that saturation was achieved within two orders of magnitude, consistent with binding to a single
recognition site.
As expected, the physiological neurosteroid 3α,5α-THP (3μM) significantly potentiated
muscimol-stimulated 36Cl- uptake (t = 4.493, df = 25, P<0.0001) (Fig 5a, inset). Increasing
concentrations of 17PA (0.1 μM – 100 μM) completely blocked 3α,5α-THP potentiation of
muscimol-stimulated 36Cl- uptake(IC50 = 30.17 μM) (Fig 5a). There was significant
potentiation of muscimol-stimulated 36Cl- uptake by the synthetic neurosteroid, alphaxalone
(3 μM) (t = -29.76, df = 5, P<0.001) (Fig 5b, inset). However, 17PA only partially attenuated
the alphaxalone potentiation of muscimol stimulation albeit with a greater potency comparison
to 3α,5α-THP (IC50 = 11.23 μM) (Fig 5b). The neurosteroid 3α,5α-THDOC (1 μM) also
significantly potentiated muscimol-stimulated 36Cl- uptake (t = -29.42, df = 4, P<0.001) (Fig
5c, inset). However, as with alphaxalone, increasing concentrations of 17PA (0.1 μM – 100
μM) only partially attenuated 3α,5α-THDOC potentiation of muscimol-stimulated 36Cl- uptake
(IC50 = 6.08 μM) (Fig 5c). Lastly, the neurosteroid non-competitive GABA-receptor antagonist
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pregnenolone sulfate (0.1 μM – 100 μM) completely blocked 3α,5α-THDOC potentiation
(IC50 = 21.64 μM)(Fig 5d).
Since 17PA did not inhibit the duration of alphaxalone hypnosis, exhibited 2-fold greater
antagonist potency for both the physiological neurosteroids 3α,5α-THP and 3α,5α-THDOC,
completely blocked the effects of 3α,5α-THP potentiation, whilst only partially attenuated the
effects of both 3α,5α-THP and 3α,5α-THDOC in the Cl- flux assay, we explored whether this
observation was dependent on the subunit diversity of the mammalian preparations. The effects
of 17PA on both 3α,5α-THDOC and alphaxalone potentiation of GABAA receptors were
explored in recombinant α1β2γ2 receptors expressed in frog oocytes. Figure 6 shows that both
3α,5α-THDOC (0.5 μM) and alphaxalone (0.5 μM) enhanced GABA-mediated Cl-
conductance to a similar extent (4.65 vs 3.55-fold increase, n = 5 and 4 oocytes respectively).
17PA (10 μM) partially inhibited the effects of both 3α,5α-THDOC and alphaxalone. These
effects were not significantly different, although the trend was for a larger effect of 17PA on
3α,5α-THDOC potentiation, with a lesser concentration of 17PA needed to obtain IC50 on 3α,
5α-THDOC potentiation (25 μM) than on alphaxalone potentiation (36 μM).
4. Discussion
17PA clearly produced a rightward shift in the dose-effect curve for 3α,5α-THP-induced
sedation and significantly reduced total sleep time. This would indicate that 17PA does
antagonize the GABA-modulatory effects of 3α,5α-THP in vivo in the mature mammalian
brain. However, 17PA did not significantly alter the sedation dose-effect curve for the synthetic
neurosteroid and anesthetic, alphaxalone, nor did 17PA significantly reduce alphaxalone total
sleep time. This may suggest that 17PA is highly selective in vivo for 3α,5α-THP. This result
is surprising since both 3α,5α-THP and alphaxalone are 5α-reduced steroids.
Differences in 17PA antagonist potency were also observed in the chloride flux assay, which
also utilizes mature native GABAA receptors of varying subtype by looking at muscimol-
stimulated 36Cl- uptake in cerebral cortical synaptoneurosomes. Analogous to the observed in
vivo sedation effects, 100 μM 17PA completely blocked 3α,5α-THP potentiation of 36Cl-
uptake, whilst only partially attenuating alphaxalone and 3α,5α-THDOC potentiation. This
further supports the notion that in the mature mammalian brain 17PA may be a more selective
antagonist for the GABA-modulatory actions of 3α,5α-THP than for the synthetic neurosteroid,
alphaxalone.
In recombinant α1β2γ2 receptors expressed in frog oocytes, 17PA has similar antagonistic
actions against 3α,5α-THDOC and alphaxalone, suggesting that 3α,5α-THDOC and
alphaxalone bind similar sites on this receptor subtype and 17PA partially inhibits neuroactive
steroid binding to the site or allosterically reduces potentiation. Consistent with past studies of
recombinant GABAA receptor preparations (Mennerick et al., 2004), 17PA exerted no direct
effect upon basal 36Cl- uptake or muscimol-stimulated 36Cl- uptake, thus further confirming
that 17PA acts a neurosteroid antagonist without any direct action on GABA recognition sites
of GABAA receptors. Interestingly, the IC50 values for 17PA antagonism of 3α,5α-THDOC
and alphaxalone are approximately 10-fold higher than the IC50 values for 17PA against 3α,
5α-THP under the same experimental conditions (Mennerick et al., 2004). This difference
parallels the higher effectiveness of 17PA on 3α,5α-THP vs. alphaxalone induced hypnosis
(Figs. 1 and 2) and steroid potentiation of chloride flux (Fig. 5). We also tested a fixed
concentration (10 μM) of 17PA against varied concentrations of alphaxalone to determine
whether electrophysiology reveals changes in potency or efficacy of the potentiator. 17PA
significantly increased the EC50 of alphaxalone potentiation (Figure 6e) without significant
changes to other fit parameters, consistent with the general conclusion that 17PA may compete
with potentiator for multiple site(s) on the GABAA α1β2γ2 receptor. This evidence that 17PA
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may interact with multiple sites on recombinant α1β2γ2 receptors was also suggested by single
channel kinetic experiments in these cells (Akk et al., 2004).
The discrepancy between the specificity of effects of 17PA for 3α,5α-THDOC vs. alphaxalone
in the loss of righting reflex assay and the Cl- flux assay compared to the recombinant receptor
prep may be attributed to the fact that mature mammalian brain contains a wide variety of
GABAA receptor subtypes with varying subunit composition and stochiometries (Sieghart and
Sperk, 2002) that may contribute to divergent steroid binding sites. It is plausible that in
vivo, alphaxalone may bind allosterically to a site on GABAA receptors that is distinct from
3α,5α-THP and this may be due to differences in receptor subtype expression intrinsic to native
receptor preparations. Alternatively, 3α,5α-THP or 3α,5α-THDOC may be metabolized in
vivo and ex vivo to contribute to the apparent effects of 17PA. However, this possibility seems
unlikely since 17PA shows the same specificity in the recombinant receptors in vitro, where
this possibility is absent.
The effect of 17PA on the chloride flux concentration response curves for both 3α,5α-THDOC
and 3α,5α-THP showed a clear conversion from biphasic saturation over more than two orders
of magnitude to monophasic saturation in exactly two orders of magnitude. This may suggest
that 17PA has no effect on at least one neurosteroid recognition site. This may help to explain
the lack of antagonist effect for alphaxalone observed in vivo. Indeed, this data might indicate
that the hypnotic effects of alphaxalone are mediated by GABAA receptor subtype(s)
containing a neurosteroid site that is insensitive to 17PA. Furthermore, the α1β2γ2 receptor
does not appear to be involved in the hypnotic effects of alphaxalone, since 17PA partially
blocked effect of alphaxalone on this receptor, but did not block hypnosis induced by
alphaxalone.
The partial inhibition of neurosteroid effects by 17PA in both the recombinant and native
GABAA receptor preparations is consistent with the idea that multiple neurosteroid sites may
exist on individual GABAA receptor subtypes (Hosie et al., 2006). Recombinant GABAA
receptors composed of β subunits alone exhibit biphasic potentiation by 3α,5α-reduced
neurosteroids (Puia et al., 1990). This phenomena may involve steroid binding of the A ring
vs. the C21 position at different sites on GABAA receptors (Purdy et al., 1990) and explain the
monophasic properties of THDOC-21 mesylate (which replaces the C21 hydroxyl group) on
GABAA receptors (Morrow et al., 1990). The ability of 17PA to partially inhibit both 3α,5α-
THDOC and alphaxalone potentiation of α1β2γ2 receptors may reflect specificity for one such
steroid binding site. However, further studies will be necessary to delineate neurosteroid
binding sites on various subtypes of GABAA receptors.
In conclusion, studies of 17PA action on native and recombinant GABAA receptors provide
further evidence for the specificity of 17PA and the heterogeneity of neurosteroid recognition
sites on GABAA receptors.
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Effects of 17PA on 3α,5α-THP-induced loss of righting reflex (LORR). a. I.c.v. administration
of the neurosteroid antagonist 17PA attenuated the sedative/hypnotic action of the
physiological neurosteroid, 3α,5α-THP. Pre-treatment with 17PA (10 nmoles) induced a
significant rightward shift in the percentage of animals exhibiting loss of righting reflex to
intravenous administration of 3α,5α-THP (0.625 – 5.0 mg/kg). b I.c.v. administration of 17PA
significantly reduced 3α,5α-THP-induced loss of righting reflex duration as revealed by a one-
way repeated measures ANOVA (F = 6.9, df =1,135, P < 0.05). A Tukey’s multiple comparison
post-hoc analyses showed that 17PA pre-treatment significantly attenuated loss of righting
reflex time induced by 3α,5α-THP at 2.0 and 2.5 mg/kg (P <0.05).
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Effects of 17PA on alphaxalone-induced loss of righting reflex. a. I.c.v. administration of 17PA
did not significantly alter sedative/hypnotic action of the synthetic neurosteroid, alphaxalone.
Pre-treatment with 17PA (10 nmoles) did not produce a significant shift in the percentage of
animals exhibiting loss of righting reflex to intravenous administration of alphaxalone (1.25 –
10.0 mg/kg). b. I.c.v. administration of 17PA does not significantly reduce alphaxalone-
induced loss of righting reflex duration as revealed by a two-way repeated measures ANOVA
(F = 0.58, df =1,104, P = 0.46).
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Effect of 17PA on basal or muscimol-stimulated 36Cl- uptake. a. 17PA (0.1 μM – 100 μM) did
not significantly alter basal 36Cl- uptake in synaptoneurosome preparations (One-way
ANOVA, F = 0.2, df = 10, p = 0.89). b. 17PA did not significantly alter 36Cl- uptake stimulated
by muscimol (1.5 μM) (F = 0.62, df = 11, p = 0.62) demonstrating no direct antagonist action
at native GABAA receptors.
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The antagonist action of 17PA on 3α,5α-THP and 3α,5α-THDOC potentiation of muscimol-
stimulated 36Cl- uptake. a. 17PA antagonism was assessed across increasing 3α,5α-THP
concentrations in rat cerebral cortical synaptoneurosomes. 17PA (open circles) did not produce
a significant rightward shift in the concentration-response curve compared to vehicle (closed
circles). However, 17PA significantly reduced 3α,5α-THP Emax (P < 0.05), therefore
attenuating maximal 3α,5α-THP potentiation of muscimol-stimulated 36Cl- uptake. b. 17PA
antagonism assessed across increasing 3α,5α-THDOC concentrations in rat cortical
synaptoneurosomes. 17PA (open circles) did not produce a significant rightward shift in the
concentration-response curve for 3α,5α-THDOC compared to vehicle (closed circles) but
significantly reduced the Emax of 3α,5α-THDOC potentiation of muscimol-stimulated 36Cl-
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uptake (P < 0.01), thus attenuating maximal 3α,5α-THDOC potentiation in the
synaptoneurosome preparation.
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Comparison of the antagonist action of 17PA on 5α-reduced steroid potentiation of muscimol-
stimulated 36Cl- uptake in rat cortical synaptoneurosomes. a. 3α,5α-THP (3 μM) potentiation
of muscimol-stimulated (1.5 μM) 36Cl- uptake relative to basal (P<0.0001, inset panel). Note
that 17PA completely blocked 3α,5α-THP potentiation of muscimol-stimulated 36Cl- uptake
(IC50 = 30.17 μM). b. Synthetic neurosteroid alphaxalone (3 μM) potentiation of muscimol-
stimulated (1.5 μM) 36Cl- uptake (P<0.001, inset panel). Note that 17PA partially attenuated
alphaxalone potentiation of muscimol stimulation (IC50 = 11.23 μM). c. 3α,5α-THDOC (1
μM) potentiation of muscimol-stimulated (1.5 μM) 36Cl- uptake (P<0.001, inset panel). 17PA
partially attenuated 3α,5α-THDOC potentiation of muscimol-stimulated 36Cl- uptake (IC50 =
6.08 μM). d. pregnenolone sulfate inhibition of 3α,5α-THDOC potentiation (IC50 = 21.64
μM).
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Responses of Xenopus oocytes expressing recombinant rat α1β2γ2 subunits to GABA co-
applied with potentiating steroids and 17PA. a. Effect of 17PA on 3α,5α-THDOC potentiation.
b. Effect of 17PA on alphaxalone potentiation. Horizontal bars indicate the duration of drug
exposure. Oocytes were clamped at -70 mV and drug concentrations were GABA (2 μM), 3α,
5α-THDOC (0.5 μM), alphaxalone (0.5 μM) and 17PA (10 μM). Responses in the two panels
were obtained from two separate oocytes. c. Inhibition curve for 17PA against 3α,5α-THDOC
in oocytes expressing recombinant receptors. 3α,5α-THDOC concentration was constant at 0.5
μM. Potentiation refers to the fractional increase over the baseline GABA response (1.0 denotes
a doubling of the response). Error bars denote standard error of the mean. The solid line is a
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fit predicting an IC50 of 25 μM. d. Similar inhibition curve for alphaxalone (0.5 μM) predicts
an IC50 of 36 μM. e. Effects of 17PA on alphaxalone concentration response parameters. The
graphs are taken from fitting a concentration response function to 8 oocytes challenged with
0.3 – 10 μM alphaxalone in the absence and presence of 10 μM 17PA. The only significant
change was a shift to the right in the alphaxalone EC50, consistent with a competitive or
pseudocompetitive mechanism of 17PA.
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